Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PfSPZ-LARC2
- Development stage
- Phase 2
- Lead developer
- Sanaria
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
PfSPZ-LARC2 is a next-generation, genetically engineered malaria vaccine developed to provide high-level protection against *Plasmodium falciparum* infection with a single dose. The vaccine uses live, attenuated sporozoites of *P. falciparum* that have been genetically modified by deleting the Mei2 and LINUP genes, which are essential for the parasite's transition from the liver stage to symptomatic blood stage infection. This genetic attenuation causes late liver-stage arrest, meaning the parasites can infect liver cells but cannot progress to cause disease in humans. As a result, PfSPZ-LARC2 induces strong humoral and cellular immune responses without risk of breakthrough blood-stage infection[1][3][4][5]. Developed by Sanaria in collaboration with Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR), this third-generation vaccine aims to achieve at least 90% protection against malaria and is being evaluated in clinical trials across multiple countries[1][2].
- Brand names
- Sanaria PfSPZ-LARC2 Vaccine
- Other names
- PfSPZ-LARC2 VaccinePfSPZ-LARC-2 VaccinePfSPZ-LARC 2 VaccineLARC2 vaccineLARC-2 vaccineLARC 2 vaccinemei2-/linup- PfSPZ
Beyond the preview
Go deeper on PfSPZ-LARC2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PfSPZ-LARC2.